Cargando…

Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score

BACKGROUND: Remdesivir was the first antiviral to show clinical benefit in patients with moderate-to-severe COVID-19. Previous trials demonstrated a faster time to recovery in hospitalized patients treated with remdesivir vs placebo. Current guidelines recommend treatment with remdesivir based on ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sellers, Jacob, Chang, Jongwha, Jones, Jessica, Hintze, Trager D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806928/ https://www.ncbi.nlm.nih.gov/pubmed/36603741 http://dx.doi.org/10.1016/j.pupt.2022.102188

Ejemplares similares

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
por: Mahajan, Lakshmi, et al.
Publicado: (2021)

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
por: Mastroianni, Antonio, et al.
Publicado: (2023)

The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury
por: Birle, Codruta, et al.
Publicado: (2020)

Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
por: Saroyo, Yudianto Budi, et al.
Publicado: (2021)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Remdesivir and Mortality in Patients With Coronavirus Disease 2019
por: Diaz, George A, et al.
Publicado: (2021)

Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma
por: Khan, Asif H, et al.
Publicado: (2022)

Reduction in the Rate of Mortality of Moderate to Severe COVID 19 Infected Patients with the use of Remdesivir - A Tertiary Care Hospital-Based Retrospective Observational Study
por: Lakhanpal, Mahima, et al.
Publicado: (2022)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
por: Arbabzadeh, Taraneh, et al.
Publicado: (2023)

A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
por: Mehta, Ravindra M., et al.
Publicado: (2021)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

Safety and Efficacy of Combination Therapy of Remdesivir, Baricitinib, and High-dose Steroids in Patients Hospitalized with Moderate to Severe COVID-19
por: Nagasawa, Ryo, et al.
Publicado: (2023)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
por: Criner, Gerard J, et al.
Publicado: (2020)

Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis
por: Karolyi, Mario, et al.
Publicado: (2022)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
por: Castagna, Antonella, et al.
Publicado: (2020)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Length of remdesivir treatment in patients with severe COVID-19
por: Ippolito, Mariachiara, et al.
Publicado: (2021)

Is It Time to Revisit Remdesivir Use for Severe COVID-19?
por: Taggarsi, Dipali Anand
Publicado: (2022)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

Esophageal impedance baseline according to different time intervals
por: Ummarino, Dario, et al.
Publicado: (2012)

The potential of HEART score to detect the severity of coronary artery disease according to SYNTAX score
por: Salimi, Amirhossein, et al.
Publicado: (2023)

The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain
por: Parsons, Bruce, et al.
Publicado: (2019)

Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia
por: Bashkin, Amir, et al.
Publicado: (2022)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score
por: Won, Ki-Bum, et al.
Publicado: (2020)

Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center
por: Mohanty, Bijaya, et al.
Publicado: (2021)

Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience
por: Attena, Emilio, et al.
Publicado: (2023)

Comparison of mortality according to baseline, first year, and mean albumin levels in peritoneal dialysis: a retrospective study
por: Çankaya, Erdem, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
por: Delanaye, Pierre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i13dfs19d44rl5klmharaatae9